Barclays PLC Increases Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Barclays PLC raised its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 127.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 361,036 shares of the company’s stock after purchasing an additional 202,248 shares during the period. Barclays PLC owned approximately 0.05% of ImmunityBio worth $1,344,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IBRX. Captrust Financial Advisors purchased a new stake in ImmunityBio in the third quarter worth approximately $41,000. Algert Global LLC purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at $86,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of ImmunityBio during the 2nd quarter valued at $105,000. Finally, Courier Capital LLC raised its position in ImmunityBio by 50.0% in the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock worth $112,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

NASDAQ:IBRX opened at $2.78 on Friday. ImmunityBio, Inc. has a 1-year low of $2.50 and a 1-year high of $10.53. The firm’s 50-day moving average price is $4.40 and its 200-day moving average price is $4.61. The company has a market capitalization of $1.94 billion, a PE ratio of -3.02 and a beta of 0.86.

Analysts Set New Price Targets

Several research firms recently issued reports on IBRX. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a report on Friday, December 20th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.